Educational content only. Not medical advice. Consult a qualified physician.
Insulin-like Growth Factor 1 Long R3 peptide
Growth HormoneResearch-only. Not FDA-approved (native IGF-1 as mecasermin/Increlex is FDA-approved for IGF-1 deficiency). LR3 variant is not an approved pharmaceutical. Banned by WADA.

IGF-1 LR3

Insulin-like Growth Factor 1 Long R3

IGF-1 LR3 is a modified version of insulin-like growth factor 1 with an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce binding to IGF-binding proteins, resulting in a longer half-life and greater bioavailability than native IGF-1. It is a potent growth factor that promotes cell proliferation and inhibits apoptosis.
Reported Benefits

Potential Benefits

  • Extended half-life compared to native IGF-1 due to reduced binding protein interaction
  • Research confirms potent mitogenic and anti-apoptotic cellular effects
  • May support muscle protein synthesis and nitrogen retention
  • Studies suggest potential for nutrient partitioning favoring lean tissue
  • Used in cell culture research to promote cell proliferation
Research Dosing

Recommended Starting Dose

20-40 mcg subcutaneously (highly experimental; carries significant metabolic risk)

Based on published research protocols. Not a prescription.

Dosing Protocol

Anecdotal protocols describe 20-80 mcg subcutaneously daily, often timed around workouts. Cycles are typically limited to 4-6 weeks due to desensitization concerns and side effect risk. Blood glucose monitoring is strongly recommended. This is one of the higher-risk peptides due to its potent growth and metabolic effects.

DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.

Research Timeline

Expected Timeline

Phase 1

Anecdotal reports describe effects on muscle fullness and recovery within 1-2 weeks. Hypoglycemic effects can occur immediately.

Regulatory

Research Status

Research-only. Not FDA-approved (native IGF-1 as mecasermin/Increlex is FDA-approved for IGF-1 deficiency). LR3 variant is not an approved pharmaceutical. Banned by WADA.

The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.

Safety Profile

Potential Side Effects

  • Hypoglycemia (significant risk; IGF-1 has insulin-like glucose-lowering effects)
  • Potential for uncontrolled cell growth and proliferation
  • Joint pain and swelling
  • Jaw, hand, and foot growth with chronic use (acromegaloid features)
  • Organ enlargement with prolonged high-dose use
  • Theoretical and epidemiological concerns about cancer risk with elevated IGF-1
  • Gut growth reported anecdotally
  • Not manufactured under pharmaceutical quality standards in most cases
Related Research

More in Growth Hormone

Medical Disclaimer

EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.